BDR Pharma launches Bdenza 160 mg for treatment of prostate cancer
Another first time ever launch of Enzalutamide 160 mg in BDR Pharma's basket was awaited by many Indian oncologists
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
BDR Pharma
Mankind Pharma and BDR Pharma come together to launch Molulife (Molnupiravir)
The tie-up is a licensing arrangement where production is by BDR Pharma and marketing, selling, promotion and distribution is by…
BDR Pharmaceuticals launches India’s first generic Midostaurin (MSTARIN) to treat Leukemia
The drug will be available in the strength of 25 mg
BDR Pharma launches biapenem to treat intra-abdominal, lower respiratory or complicated urinary…
BIAPENEM is launched under the brand name BIAPEN, in addition to their existing vast range of antibiotics
BDR Pharmaceuticals set to launch maiden generic Cabozantinib to treat metastatic medullary thyroid…
The company is amongst the first to receive permission from DCGI and launch the drug in India
Mankind Pharma partners with BDR Pharma to distribute Baricitinib in India
BDR Pharma will be manufacturing and marketing the product under a royalty-free, limited and non-exclusive voluntary licence from…
BDR Pharma launches generic Rucaparib to treat advanced ovarian and prostate cancers
Rucaparib is launched under the brand name BDPARIB in two strengths of 200 mg and 300 mg
BDR Pharma signs voluntary licensing agreement with Lilly for baricitinib
Lilly had recently announced seven other voluntary license agreements with major drug manufacturers in India for the production of…
BDR Pharma launches generic version of Lenvatinib in India
It is indicated for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer
BDR Pharma launches Nintenib (Nintedanib) to treat idiopathic pulmonary fibrosis in India
Nintenib is priced at Rs 750 (100 mg) and INR 900 (150 mg) for a pack of 10 tabs